{'fraction_non_alphanumeric': 0.017002237136465325, 'fraction_numerical': 0.0, 'mean_word_length': 6.1210191082802545, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Acute Therapy of Bacterial Meningitis

Antimicrobial therapy for bacterial meningitis has markedly reduced mortality rates from this disorder. The efficacy of an antibiotic in meningitis depends on many factors, including its penetration into cerebrospinal fluid (CSF), the bactericidal efficacy of the antibiotic within purulent CSF, and the need for bactericidal activity in CSF because bacterial meningitis represents an infection in an area of impaired host defense. Penicillin G and ampicillin are equally efficacious for meningitis caused by Streptococcus pneumoniae or Neisseria meningitidis. This recommendation may change, however, with the emergence of strains of pneumococci or meningococci that are relatively or highly resistant to penicillin; a third-generation cephalosporin (cefotaxime or ceftriaxone) should be used for meningitis due to relatively resistant strains and vancomycin for pneumococcal meningitis caused by strains that are highly resistant to penicillin. With the high percentage of strains of Haemopbilus influenzae type b that produce β-lactamase, empiric therapy when this organism is suspected should consist of a third-generation cephalosporin; these agents are also used for meningitis caused by enteric gram-negative bacilli, and one agent, ceftazidime, is effective against Pseudomonas aeruginosa meningitis. Despite the availability of effective bactericidal antibiotics, morbidity and mortality from bacterial meningitis remains unacceptably high. Recent studies using animal models of infection have demonstrated the beneficial effect of antiinflammatory agents in attenuating the CSF inflammatory response that may lessen many of the pathophysiological consequences of meningitis. Studies of adjunctive dexamethasone therapy suggest that these agents may reduce morbidity (specifically sensorineural hearing loss) and mortality (due to S. pneumoniae) in patients with bacterial meningitis. Controversy remains, however, concerning the use of dexamethasone in all patients with bacterial meningitis and further studies are necessary. In critically ill patients with bacterial meningitis, control of increased intracranial pressure and seizures may be useful and necessary in improving outcome.